MedTrace Logo

Personalised Therapy for Metastatic ADPC Determined by Genetic Testing and Avatar Model Generation

NCT02795650 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2021-02-26

No results posted yet for this study

Summary

This is a multicenter, open label, randomised phase II clinical trial for patients with metastatic adenocarcinoma of the pancreas. Patients randomised to the experimental arm will undergone tumoral biopsy before starting first line of treatment and will be administered personalised therapy as second or third line.

Conditions

  • Adenocarcinoma

Interventions

DRUG

Personalised treatment

Personalised treatments include chemotherapy, targeted therapy, immunotherapy or others based on the previous test results, chosen from a database that include more than 2000 different drugs.

DRUG

Treatment chosen per investigator´s judge

Investigators are allowed to chose what they consider the best standard treatment option for their patients.

Sponsors & Collaborators

  • Hospital Universitario de Fuenlabrada

    lead OTHER

Principal Investigators

  • Manuel Hidalgo, PhD · Beth Israel Deaconess Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2021-09-30
Completion
2022-09-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02795650 on ClinicalTrials.gov